SageView Advisory Group’s Cellectis CLLS Stock Holding History

SageView Advisory Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-115	Closed	-$557	–	937
2025 Q4	$557	Buy	+115	New	+$481	﹤0.01%	2438

Other funds holding CLLS

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SageView Advisory Group's CLLS Position: Q1 2026 in Review

SageView Advisory Group sold out of Cellectis (CLLS) in Q1 2026, closing a stake of 115 shares — an estimated $557 sold.

SageView Advisory Group first reported a position in CLLS in Q4 2025 and held it in 1 quarter. The position peaked at $557 in Q4 2025. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.

SageView Advisory Group reported no remaining Cellectis position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 115 Cellectis shares in Q1 2026, an estimated $557.
SageView Advisory Group first reported a position in Cellectis in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Cellectis position peaked at $557 in Q4 2025.
32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.